Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

HK Type 4 license through Ballingal Investment Advisors Ltd. 

I'm a highly experienced sell-side analyst with in excess of 22 years of covering Asia Pacific equities, the past 19 years immersed in event strategies encompassing M&A risk arbitrage, directional long/short, stub trades and restructuring.  

My background also includes accountancy (liquidation/bankruptcy/receivership) earlier in my career and as a chief financial officer of a global commodity company based in the US and Mexico.

Pan-Asia Catalysts/Events

Genetron (泛生子) IPO Trading: Priced at Our Fair Value, yet There Could Be Upside

Genetron (泛生子) IPO: Metrics Inferior to Burning Rock

Genetron (泛生子) Pre-IPO: Positive Development but Tracking Behind Burning Rock

Quiddity Advisors

Event-Driven

<ul>
<li>Back on the <a href="https://ir.genetronhealth.com/news-releases/news-release-details/genetron-health-enters-definitive-merger-agreement-going-private" target="_blank" rel="noopener">11th October 2023</a>, <strong><a href="https://www.smartkarma.com/entities/genetron-holdings-ltd" target="_blank" data-smartkarma-citation="entities:28435:1" rel="noopener">Genetron Holdings Ltd (GTH US)</a></strong>, a precision oncology platform, entered into a definitive take-private transaction, at $4.08/ADS, a 15% premium to undisturbed.</li>
<li>The EGM for shareholders to vote on the transaction will be held on the <a href="https://ir.genetronhealth.com/news-releases/news-release-details/genetron-health-hold-extraordinary-general-meeting-shareholders" target="_blank" rel="noopener">21 February</a>. The record date is the 9 Feb.</li>
<li>This merger requires approval from at least two-thirds of the votes cast, and 59.7% are supportive. Trading at a gross spread of 7.7%. This is a clean deal.</li>
</ul>


Back on the 11th October 2023, Genetron Holdings Ltd (GTH US), a precision oncology platform, entered into a definitive take-private transaction, at $4.08/ADS, a 15% premium to undisturbed.
The EGM for shareholders to vote on the transaction will be held on the 21 February. The record date is the 9 Feb.
This merger requires approval from at least two-thirds of the votes cast, and 59.7% are supportive. Trading at a gross spread of 7.7%. This is a clean deal.


Genetron Holdings (GTH US): Clear Diagnosis